Drugs in Dev. Infections and Infectious Diseases
Phase I/ Phase II
Canada 
Lead Product(s) : AP-003
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Studies are ongoing to validate preliminary results and to test rhIFN⍺2b activity against Gamma (Brazil), Lambda (Peru), and the recent C.1.2 (South Africa) variant which contains mutations associated with increased transmissibility and the ability to ...
Product Name : AP-003
Product Type : Protein
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : AP-003
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AP-003
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AP-003 is an anti-viral, recombinant human interferon alpha-2b product proven to be an effective treatment against COVID-19 successfully completed the Phase 1 portion of the Phase 1-2 randomized placebo controlled trial.
Product Name : AP-003
Product Type : Protein
Upfront Cash : Inapplicable
November 29, 2021
Lead Product(s) : AP-003
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
